viruslik
particl
vlp
form
selfassembl
envelop
andor
capsid
protein
mani
virus
mani
case
vlp
structur
characterist
antigen
similar
parent
viru
alreadi
proven
success
vaccin
cognat
viru
infect
structur
compon
vlp
also
proven
amen
insert
fusion
foreign
antigen
sequenc
allow
product
chimer
vlp
expos
foreign
antigen
surfac
vlp
use
carrier
foreign
antigen
includ
nonprotein
antigen
via
chemic
conjug
review
outlin
advantag
disadvantag
technic
consider
use
wide
rang
vlp
system
vaccin
develop
structur
protein
mani
virus
abil
assembl
repeat
array
viruslik
particl
vlp
follow
recombin
dna
express
varieti
cultur
system
vlp
fall
gener
size
rang
virus
nm
exact
size
morpholog
depend
particular
viral
protein
incorpor
vlp
noninfecti
assembl
without
incorpor
genet
materi
vlp
promis
approach
product
vaccin
mani
diseas
repetit
high
densiti
display
epitop
often
evect
elicit
strong
immun
respons
enhanc
particul
natur
vlp
especi
size
rang
around
nm
appear
optim
uptak
nanoparticl
dendrit
cell
case
vlp
similar
natur
occur
subvir
particl
svp
exampl
express
small
envelop
protein
hepat
b
viru
hbv
yeast
mammalian
cell
lead
format
nm
vlp
essenti
ident
svp
natur
product
hbv
infect
found
patient
blood
level
far
greater
virion
notabl
plasmaderiv
svp
provid
wrstgener
hbv
vaccin
similarli
express
protein
human
papillomaviru
lead
assembl
vlp
somewhat
similar
empti
viru
particl
form
papillomaviru
replic
although
natur
empti
particl
also
contain
protein
recombin
human
papillomaviru
vaccin
base
protein
hpv
expect
licens
near
futur
exampl
vlp
vaccin
candid
shown
tabl
case
vlp
exploit
platform
present
foreign
epitop
andor
target
molecul
chimer
vlp
achiev
modiwc
vlp
gene
sequenc
fusion
protein
vlp
protein
foreign
vaccin
protein
assembl
vlp
de
novo
synthesi
fusion
peptid
sequenc
core
gene
hbcag
hepat
b
viru
provid
earli
exampl
approach
altern
foreign
vaccin
protein
may
chemic
conjug
preform
vlp
one
exampl
approach
use
product
hbcag
vlp
contain
extracellular
domain
ion
channel
protein
inxuenza
viru
chemic
conjug
approach
also
allow
vlp
exploit
nonprotein
antigen
nicotin
exampl
chimer
vlp
shown
tabl
diver
virus
provid
varieti
build
block
product
vlp
nonenvelop
virus
hpv
core
particl
envelop
virus
hbcag
one
chimer
capsid
protein
express
selfassembl
multipl
capsid
protein
may
assembl
either
express
subsequ
process
precursor
protein
coexpress
capsid
protein
bicistron
multicistron
vector
cell
envelop
virus
vlp
assembl
envelop
protein
without
matrixcapsid
protein
form
authent
viral
particl
either
case
envelop
protein
bud
usual
cellular
compart
er
plasma
membran
lipid
raft
associ
plasma
membran
thu
contain
cellular
lipid
make
viral
lipoprotein
envelop
instanc
vlp
may
also
includ
host
cell
protein
exampl
lipid
raft
associ
gangliosid
ebola
marburg
vlp
hiv
help
evad
complement
lysi
vlp
commonli
immunogen
subunit
recombin
protein
immunogen
abl
stimul
humor
cellular
arm
immun
system
vlp
provid
spatial
structur
display
conform
epitop
like
mimic
nativ
viru
structur
therebi
enhanc
product
neutral
antibodi
may
especi
true
surfac
protein
parasit
envelop
virus
envelop
vlp
allow
vaccin
protein
present
natur
state
membranebound
protein
rather
solubl
ectodomain
alon
vlp
may
therefor
safe
evect
approach
induct
antibodi
surfac
protein
solubl
form
protein
fail
evect
vlp
also
capac
present
multipl
vaccin
protein
immun
system
despit
success
hbv
vaccin
improv
eycaci
sought
inclus
larg
middl
envelop
protein
hbsag
particl
therebi
mimick
authent
virion
envelop
contain
three
protein
hbv
vaccin
includ
addit
envelop
protein
vari
extent
elicit
antibodi
respons
protein
specif
provid
addit
cell
epitop
promot
earlier
antihbsag
respons
improv
seroprotect
rate
overcom
nonrespons
hbsag
vaccin
inxuenza
viru
present
exampl
recombin
vlp
develop
close
mimic
nativ
viru
particl
inxuenza
vlp
similar
size
nativ
inxuenza
viru
particl
around
nm
provid
use
altern
eggderiv
cellcultur
deriv
vaccin
base
inactiv
viru
howev
larg
size
inxuenza
vlp
may
optim
immunogen
hiv
present
anoth
exampl
substanti
evort
made
recreat
virion
envelop
form
permit
eycient
induct
broadli
neutralis
antibodi
includ
product
synthet
proteoliposom
solid
microspher
bead
order
mimic
lipid
membran
environ
present
hiv
well
vlp
mimick
intact
hiv
particl
contain
envelop
protein
associ
viral
gag
protein
core
see
extens
review
hiv
vlp
vaccin
evolv
increas
knowledg
envelop
structur
xray
crystallographi
mutat
analysi
key
envelop
domain
associ
viral
entri
coupl
understand
conserv
region
unlik
undergo
antigen
variat
immun
pressur
essenti
target
elicit
broadli
neutralis
antibodi
respons
review
recent
research
focus
present
highli
conserv
neutral
epitop
envelop
protein
prefus
conform
briexi
expos
viral
entri
review
mcgaughey
speciwc
goal
vaccin
develop
like
requir
experiment
wide
varieti
vlp
express
system
avail
use
function
assay
receptor
bind
reactiv
conformationspeciwc
antibodi
importantli
induct
broadli
crossneutr
antibodi
mean
conwrm
appropri
envelop
protein
fold
vaccin
eycaci
case
vlp
appear
requir
use
adjuv
achiev
potent
immun
stimul
selfadjuv
evect
vlp
inher
tendenc
suitabl
size
uptak
dendrit
cell
dc
process
present
mhc
class
ii
directli
promot
dc
matur
migrat
essenti
stimul
innat
immun
respons
exogen
vlp
also
taken
process
via
mhc
class
pathway
crosspresent
activ
tcell
essenti
clearanc
intracellular
pathogen
virus
abil
vlp
target
dc
import
advantag
vlp
vaccin
target
cell
type
understood
essenti
activ
innat
adapt
immun
respons
vlp
resembl
infecti
virus
retain
receptor
bind
region
abl
target
enter
cell
via
normal
receptor
taken
antigen
present
cell
exogen
antigen
class
present
receptormedi
uptak
shown
occur
via
sialic
acid
interact
haemagglutinin
phage
qbeta
nicotin
e
coli
neuraminidas
paramyxovirus
interact
bind
cell
hcv
envelopespeciwc
receptor
involv
still
unclear
stimul
dc
produc
cytokin
interferon
requir
replic
viru
rather
intact
envelop
either
inactiv
viru
vlp
shown
ebola
marburg
virus
intact
nonenvelop
vlp
hpv
context
vlp
may
advantag
cognat
live
virus
immun
activ
sever
virus
replic
dc
known
block
activ
matur
cell
express
particular
viral
protein
even
inactiv
ebola
marburg
virus
still
interfer
dc
activ
suggest
viral
protein
present
viru
vlp
respons
vlp
produc
capsid
envelop
compon
wide
varieti
virus
purpos
studi
viral
assembl
develop
vaccin
hbv
hpv
vlp
made
success
vaccin
pathogen
directli
avect
immun
cell
success
evad
immun
system
hepat
c
viru
proven
challeng
clear
mani
individu
expos
larg
amount
authent
viral
particl
year
chronic
infect
without
develop
fulli
evect
immun
respons
suggest
vlp
may
also
prove
inevect
even
close
mimic
nativ
viral
structur
candid
may
thu
requir
adapt
vlp
design
particl
size
envelop
structur
target
host
dc
mucos
surfac
rout
administr
achiev
desir
immun
respons
chimer
vlp
provid
mean
incorpor
heterolog
antigen
vlp
includ
antigen
unabl
selfassembl
particul
form
ctl
epitop
fragment
envelop
protein
antigen
virus
intact
viru
particl
may
optim
immunogen
hiv
hcv
chimer
vlp
may
consist
homolog
vlp
platform
assembl
fusion
epitop
multipl
strain
viru
addit
epitop
core
vlp
structur
fusion
nonstructur
protein
capsid
protein
hpv
altern
chimer
vlp
may
consist
vlp
platform
present
polyprotein
epitop
total
unrel
viru
pathogen
eg
hbv
core
vlp
malaria
human
rhinoviru
epitop
inxuenza
major
limit
vlp
platform
small
size
foreign
epitop
accommod
within
particl
preclud
present
larg
antigen
hiv
envelop
inxuenza
haemagglutinin
protein
tailor
vlp
may
also
inxuenc
whether
vaccin
act
prophylact
therapeut
vaccin
latter
thought
requir
inclus
speciwc
cell
epitop
ctl
base
clearanc
hbv
vaccin
case
hpv
oncogen
protein
evect
vlp
therapeut
vaccin
may
aid
addit
adjuv
cpg
stimul
dc
via
tolllik
receptor
precis
colocalis
coevect
vlpadjuv
made
possibl
techniqu
packag
cpg
vlp
vaccin
chimer
hepat
b
core
vlp
ctl
epitop
lymphocyt
choriomening
viru
glycoprotein
packag
cpg
abl
induc
high
frequenc
peptid
speciwc
cell
cure
mice
wbrosarcoma
tumour
singl
dose
moreov
evect
vlp
cellbas
vaccin
increas
administ
part
dna
primevlp
boost
protocol
way
utilis
vlp
deliveri
platform
chemic
crosslink
peptid
epitop
reactiv
site
platform
done
coupl
peptid
contain
free
cystein
residu
lysin
situat
immunodomin
expos
region
hbv
core
particl
chimer
vlp
enorm
potenti
select
multiepitop
present
success
depend
clear
understand
correl
immun
clearanc
protect
includ
select
relev
epitop
vaccin
eycaci
knowledg
lack
mani
diseas
numer
chimer
vlp
tabl
second
gener
recombin
hbv
vaccin
scibvac
biohepb
shown
progress
clinic
trial
vlp
includ
two
addit
envelop
protein
l
found
nm
virion
protein
incorpor
much
lower
level
particl
nm
size
notabl
vaccin
retain
major
compon
wrstgener
recombin
hbsag
vaccin
well
l
protein
mani
express
system
product
vlp
includ
variou
mammalian
cell
line
either
transient
stabli
transfect
transduc
viral
express
vector
baculovirusinsect
cell
system
variou
speci
yeast
includ
saccharomyc
cerevisia
pichia
pastori
escherichia
coli
bacteria
oral
vaccin
initi
also
produc
hbv
norwalk
viru
vlp
variou
plant
includ
tobacco
lettuc
leav
well
potato
eas
express
abil
scaleup
cost
product
made
yeast
popular
choic
howev
consider
appropri
protein
glycosyl
correct
fold
assembl
well
codon
optimis
may
dictat
altern
product
system
e
coli
allow
glycosyl
yeast
baculoviru
limit
high
mannos
glycoprotein
modiwc
sometim
inconsist
baculovirusdriven
express
inxuenza
vlp
provid
novel
challeng
separ
progeni
baculoviru
vector
particl
inxuenza
vlp
similar
size
rang
nm
mammalian
cell
cultur
system
favour
appropri
modiwc
authent
assembl
less
control
system
costli
product
retrovirus
particular
also
tend
includ
unwant
host
cell
membran
protein
envelop
assembl
futur
direct
manufactur
may
includ
approach
vitro
chemic
selfassembl
vlp
base
wrst
instanc
capsid
compon
wide
varieti
vlp
shown
promis
result
small
anim
model
may
great
potenti
develop
vaccin
mani
diycult
target
diseas
howev
manufactur
consider
like
limit
practic
util
mani
vlp
approach
small
size
vaccin
antigen
incorpor
vlp
may
also
prove
signiwc
barrier
vaccin
eycaci
anticip
licensur
human
papillomaviru
vlp
vaccin
undoubtedli
provid
stimulu
weld
